An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development

Journal of Pharmaceutical Sciences

Volumn 104, Issue 9, 2015, Pages 3154-3161

  Yamashita, Shinji ^a   Kataoka, Makoto ^a   Suzaki, Yuki ^b   Imai, Hiromitsu ^b   Morimoto, Takuya ^b   Ohashi, Kyoichi ^b   Inano, Akihiro ^c   Togashi, Kazutaka ^d   Mutaguchi, Kuninori ^d   Sugiyama, Yuichi ^e  

^a SETSUNAN UNIVERSITY   (Japan)

^b OITA UNIVERSITY HOSPITAL   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d Sumika Chemical Analysis Service   (Japan)

^e RIKEN   (Japan)

Author keywords

bioavailability; cassette dose; clinical study; dose proportionality; first pass metabolism; microdose; Nonlinear pharmacokinetics; oral absorption

Indexed keywords

DILTIAZEM; NICARDIPINE; NIFEDIPINE; CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MICRODOSE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; ADULT; BIOAVAILABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, LIQUID; DILTIAZEM; HUMANS; MALE; MASS SPECTROMETRY; NICARDIPINE; NIFEDIPINE; YOUNG ADULT;

EID: 84939260630     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24499     Document Type: Article

References (31)

1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J,. 2014. Clinical development success rates for investigational drugs. Nat Biotechnol 32: 40-51.
2. Kola I, Landis J,. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
3. ICH Harmonised Tripartite Guideline. 2009. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Dated 11 June 2009, Accessed at: http://www.ich.org/.
4. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC,. 2006. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clin Pharmacol Ther 80: 203-215.
5. Lappin G, Garner R.C,. 2008. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol. 4: 1499-1506.
6. Sugiyama Y, Yamashita S,. 2011. Impact of microdosing clinical study-Why necessary and how useful? Adv Drug Deliv Rev 63: 494-502.
7. Roberts SA., 2003. Drug metabolism and pharmacokinetics in drug discovery. Curr Opin Drug Discov Dev 6: 66-80.
8. Tang H, Mayersohn M,. 2005. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33: 1297-1303.
9. Mahmood I, Martinez M, Hunter RP,. 2006. Interspecies allometric scaling. Part I: Prediction of clearance in large animals. J Vet Pharmacol Ther 29: 415-423.
10. Takahashi M, Washio T, Suzuki N, Igeta K, Yamashita S,. 2009. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98: 4343-4353.
11. Toutain PL, Ferran A, Bousquet-Mélou A,. 2010. Species differences in pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol 199: 19-48.
12. Sietsema WK., 1989. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27: 179-211.
13. Musther H, Olivares-Morales A, Hatley OJ, Liu B, Rostami Hodjegan A,. 2014. Animal versus human oral drug bioavailability: Do they correlate? Eur J Pharm Sci 57: 280-291.
14. Yamane N, Tozuka Z, Kusama M, Maeda K, Ikeda T, Sugiyama Y,. 2011. Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies. Pharm Res 28: 1963-1972.
15. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y,. 2011. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90: 575-581.
16. Echizen H, Eichelbaum M,. 1986. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 11: 425-449.
17. Graham DJ, Dow RJ, Hall DJ, Alexander OF, Mroszczak EJ, Freedman D,. 1985. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol 20 (Suppl 1): 23S-28S.
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). 2001. Guidance for industry. Bioanalytical method validation. Dated May 2001. Accessed at: at http://www.fda.gov/.
19. Kölle EU, Ochs HR, Vollmer KO,. 1983. Pharmacokinetic model of diltiazem. Arzneimittelforschung 33: 972-977.
20. Lappin G, Noveck R, Burt T,. 2013. Microdosing and drug development: Past, present and future. Expert Opin Drug Metab Toxicol 9: 817-834.
21. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H,. 1996. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24: 1121-1123.
22. Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S, Ishizaki T,. 2000. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: Evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol 56: 643-649.
23. Christensen H, Asberg A, Holmboe AB, Berg KJ,. 2002. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 58: 515-520.
24. Raemsch KD, Sommer J,. 1983. Pharmacokinetics and metabolism of nifedipine. Hypertension 5 (4 Pt 2):I I18-24.
25. Hermann P, Rodger SD, Remones G, Thenot JP, London DR, Morselli PL,. 1983. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol 24: 349-352.
26. Higuchi S, Shiobara Y,. 1980. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotic 10: 447-454.
27. Wagner JG, Ling TL, Mroszczak EJ, Freedman D, Wu A, Huang B, Massey IJ, Roe RR,. 1987. Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. Biopharm Drug Dispos 8: 133-148.
28. Inotsume N, Iwaoka T, Honda M, Nakano M, Okamoto Y, Naomi S, Tomita K, Teramura T, Higuchi S,. 1997. Pharmacokinetics of nicardipine enantiomers in healthy young volunteers. Eur J Clin Pharmacol 52: 289-292.
29. Ochs HR, Knüchel M,. 1984. Pharmacokinetics and absolute bioavailability of diltiazem in humans. Klin Wochenschr 62: 303-306.
30. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L,. 2005. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60: 54-60.
31. Richter O, Burk O, Fromm M, Thon K, Eichelbaum M, Kivistö K,. 2004. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75: 172-183.